Corporate Overview
Advaxis is a Phase 2 stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live attenuated Listeria monocytogenes (Lm) that are bio-engineered to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to Lm to the cancer itself.
| ADVAXIS INC (OTC BB: ADXS.OB) | 2/22/2012 3:20pm | ||||||||||||||||||
| 1d | 5d | 3m | 6m | 1y | 2y | 5y | Max |
Recent SEC Filings
- 424B3 – Prospectus [Rule 424(b)(3)] February 7, 2012
- EFFECT – Notice of Effectiveness February 7, 2012
- S-1 – General form for registration of securities under the Securities Act of 1933 January 27, 2012
- 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] January 26, 2012
- 8-K – Current report January 5, 2012
Board of Directors Management Team
Thomas A. Moore Thomas A. Moore
Dr. James Patton Dr. John Rothman
Roni A. Appel Mark Rosenblum
Dr. Thomas McKearn Dr. Robert Petit
Richard Berman